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Summary  Psychological  stress  may  contribute  to  type  2  diabetes  but  mechanisms  are  still
poorly understood.  In  this  study,  we  examined  whether  stress  responsiveness  is  associated
with glucocorticoid  and  mineralocorticoid  sensitivity  in  a  controlled  experimental  compar-
ison of  people  with  type  2  diabetes  and  non-diabetic  participants.  Thirty-seven  diabetes
patients  and  37  healthy  controls  underwent  psychophysiological  stress  testing.  Glucocorticoid
(GR) and  mineralocorticoid  sensitivity  (MR)  sensitivity  were  measured  by  dexamethasone-  and
prednisolone-inhibition  of  lipopolysaccharide  (LPS)-induced  interleukin  (IL)  6  levels,  respec-
tively. Blood  pressure  (BP)  and  heart  rate  were  monitored  continuously,  and  we  periodically
assessed salivary  cortisol,  plasma  IL-6  and  monocyte  chemotactic  protein  (MCP-1).  Following
stress, both  glucocorticoid  and  mineralocorticoid  sensitivity  decreased  among  healthy  controls,
but did  not  change  in  people  with  diabetes.  There  was  a  main  effect  of  group  on  dexamethasone
(F(1,74) =  6.852,  p  =  0.013)  and  prednisolone  (F(1,74) =  7.295,  p  =  0.010)  sensitivity  following  stress
at 45  min  after  tasks.  People  with  diabetes  showed  blunted  stress  responsivity  in  systolic  BP,
diastolic BP,  heart  rate,  IL-6,  MCP-1,  and  impaired  post-stress  recovery  in  heart  rate.  People  with
Diabetes had  higher  cortisol  levels  as  measured  by  the  total  amount  excreted  over  the  day  and
increased glucocorticoid  sensitivity  at  baseline.  Our  study  suggests  that  impaired  stress  respon-
sivity in  type-2  diabetes  is  in  part  due  to  a  lack  of  stress-induced  changes  in  mineralocorticoid
and glucocorticoid  sensitivity.
©  2014  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under  the  CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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1.  Introduction
Patients  with  type  2  diabetes  have  a  substantially  increased
risk  of  developing  coronary  heart  disease  (CHD)  as  well  as
poorer  long-term  prognosis  following  myocardial  infarction
http://dx.doi.org/10.1016/j.psyneuen.2014.09.023
0306-4530/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).
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(Haffner  et  al.,  1998;  Mukamal  et  al.,  2001;  Yusuf  et  al.,
2004).  Recently,  some  mechanisms  on  how  inﬂammation
could  play  a  role  in  diabetes  have  been  described,  and
could  play  a  role  in  CHD  risk.  For  example,  low-grade  local
and  systemic  inﬂammation  in  -cells  of  pancreatic  islets
and  peripheral  tissues  to  induce  -cells’  dysfunction  and
apoptosis,  insulin  resistance,  and  ultimately,  overt  type  2
diabetes  mellitus  (T2DM)  (Akash  et  al.,  2013a).  Despite  this,
the  mechanisms  underlying  the  association  between  dia-
betes  and  CHD  are  not  completely  clear.  Psychological  stress
may  contribute  to  risk  of  developing  CHD  in  people  with  dia-
betes.  Longitudinal  studies  have  also  conﬁrmed  an  increased
risk  of  developing  diabetes  in  people  with  high  levels  of
stress  (Eriksson  et  al.,  2008;  Chida  and  Hamer,  2008;  Nyberg
et  al.,  2014).  People  who  experience  depression  also  present
increased  risk  of  future  diabetes  (Rotella  and  Mannucci,
2013).
Psychological  stress  has  been  linked  to  production  of  pro-
inﬂammatory  markers  and  these  effects  may  mediate  the
inﬂuence  of  psychosocial  factors  on  cardiovascular  risk  in
people  with  diabetes  (Steptoe  et  al.,  2007).  There  is  evi-
dence  that  elevated  inﬂammatory  responses  in  people  with
diabetes  play  an  important  role  in  linking  diabetes  with
increased  incidence  of  atherosclerosis  (Ray  et  al.,  2009).
Diabetes  patients  with  raised  levels  of  C-reactive  protein
are  30%  more  likely  to  have  cardiovascular  events  than  those
without  inﬂammation  (Akash  et  al.,  2013b).  Treatment  with
anti-inﬂammatory  drugs  are  currently  being  investigated  to
dampen  the  effects  of  T2DM  inducers  (Akash  et  al.,  2012,
2013c).
Apart  from  traditional  risk  factors,  stress-induced
inﬂammation  may  be  an  additional  mechanism  in  peo-
ple  with  diabetes.  Psychological  stress  activates  the
hypothalamus—pituitary—adrenal  (HPA)  axis  that  regulates
inﬂammation.  Hyperactivation  of  the  HPA  axis  has  been
reported  in  patients  with  diabetes  (Cameron  et  al.,  1984;
Roy  et  al.,  1990,  1993),  and  is  associated  with  coronary  heart
disease  and  its  risk  factors  (Reynolds  et  al.,  2010).  Patients
with  diabetes  present  alterations  of  the  HPA  axis  negative
feedback  (Bruehl  et  al.,  2007)  suggestive  of  an  impairment
of  corticosteroid  receptor  sensitivity.  HPA  axis  disturbance
seems  to  be  particularly  important  in  people  with  diabetes
since  the  degree  of  cortisol  secretion  is  related  to  the  pres-
ence  and  number  of  diabetes  complications  (Chiodini  et  al.,
2007).
Psychosocial  stress  regulates  the  effect  of  corticosteroids
on  target  tissues  via  dynamic  modulation  of  corticosteroid
sensitivity  (Rohleder  et  al.,  2003).  Two  distinct  intracellu-
lar  sensitivity  subtypes  mediate  the  effect  of  cortisol:  the
type  I  or  mineralocorticoid  sensitivity  (MR)  and  the  type  II
or  glucocorticoid  sensitivity  (GR)  (de  Kloet  et  al.,  1998).
Dexamethasone  activates  human-GR-mediated  gene  tran-
scription,  but  even  at  the  highest  concentrations  is  unable
to  fully  activate  human-MR-mediated  gene  transcription
(Rupprecht  et  al.,  1993).  On  the  other  hand,  prednisolone  is
a  synthetic  glucocorticoid  that  is  more  similar  to  cortisol  in
its  capacity  to  bind  and  activate  the  GR  and  the  MR,  espe-
cially  when  compared  with  dexamethasone.  Thus,  the  effect
of  corticosteroids  on  the  regulation  of  inﬂammation  during
stress  will  depend  not  only  on  the  actual  basal  levels  of  cor-
tisol,  but  also  on  stress-induced  changes  in  the  sensitivity  of
both  glucocorticoid  and  mineralocorticoid  receptors.
As  part  of  a  larger  study  of  stress  processes  in  type
2  diabetes  participants,  we  assessed  stress-related  mod-
ulation  of  GR  and  MR  sensitivity  in  a  subset  of  patients
randomly  selected.  Such  alterations  may  provide  a  new  bio-
logical  mechanism  linking  diabetes  with  elevated  levels  of
inﬂammation  and  the  elevated  risk  of  acute  cardiovascular
syndrome  following  stress.  We  analysed  the  glucocorti-
coid  and  mineralocorticoid  sensitivity  of  lipopolysaccharide
(LPS)-induced  IL-6  production  in  whole  blood  of  people  with
diabetes  and  healthy  controls.  All  participants  underwent
a  standardized  acute  psychological  stress  test  (Zalli  et  al.,
2014),  and  we  measured  MR  and  GR  sensitivity  of  IL-6  pro-
duction  at  different  time  points  before  and  after  stress.  We
measured  IL-6  because  it  seems  to  play  an  important  role  in
how  psychological  stress  contributes  to  physical  and  mental
illness.  IL-6  is  also  involved  in  the  activation  of  the  inﬂam-
matory  cascade  that  leads  to  the  production  of  C-reactive
protein  by  the  liver.  To  obtain  each  measure  of  glucocor-
ticoid  and  mineralocorticoid  sensitivity  we  calculated  the
amount  of  dexamethasone  and  prednisolone,  respectively
that  was  necessary  to  suppress  LPS-induced  IL-6  levels  by
50%.  Moreover,  we  measured  blood  pressure,  heart  rate,
salivary  cortisol,  and  inﬂammatory  cytokines  such  as  IL-6
and  MCP-1  before  and  after  stress  to  assess  the  amount  of
stress  induced  by  the  behavioural  tasks.
2. Methods
2.1.  Participants
This  is  a  sub-study  of  a  larger  cohort  of  type  2  diabetic
patients  (T2DM)  recruited  from  primary  care  clinics  in  the
London  area  who  participated  in  a  mental  stress  proto-
col  (Steptoe  et  al.,  2001,  2002a).  For  this  particular  study,
cells  were  collected  from  thirty-seven  diabetes  partici-
pants  and  37  healthy  controls  by  simple  random  sampling.
Glucocorticoid  sensitivity  function  was  analysed  in  a  sub-
group  of  20  people  from  each  group.  Participants  gave  fully
informed  written  consent  to  participate  in  the  study  and
ethical  approval  was  obtained  from  the  National  Research
Ethics  Service.  We  limited  enrolment  to  diabetes  partici-
pants  without  a  history  or  previous  diagnosis  of  coronary
heart  disease  (CHD),  inﬂammatory  diseases,  allergies  or
mood  disorders,  but  had  no  other  exclusion  criteria.  Healthy
controls  were  recruited  from  the  subsample  of  the  White-
hall  II  epidemiological  cohort  recruited  between  2006  and
2008  to  investigate  socioeconomic  and  psychosocial  factors,
physiological  stress  responsivity,  and  subclinical  coronary
artery  disease  (Hamer  et  al.,  2010).  Healthy  participants
were  white  European  origin  with  no  history  or  objective  signs
of  CHD,  no  previous  diagnosis  or  treatment  for  hypertension,
diabetes,  inﬂammatory  diseases,  or  allergies.  The  absence
of  diabetes  was  conﬁrmed  by  low  glycated  haemoglobin
(HbA1c)  levels  (≤6.5%)  and  negative  oral  glucose  tolerance
tests  over  the  previous  20  years.  Participants  underwent
identical  mental  stress  testing  to  that  carried  out  with  the
diabetes  group.
2.2.  Mental  stress  tasks
Mental  stress  was  induced  in  the  laboratory  using  two  5-
min  behavioural  tasks:  the  Stroop  colour-word  interference
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and  mirror  tracing.  These  tasks  were  selected  because  they
have  been  shown  to  stimulate  cardiac  responses  (Steptoe
et  al.,  2002a),  and  have  been  used  in  a  number  of  previ-
ous  studies  in  our  laboratory  (Steptoe  et  al.,  2001,  2002a;
Zalli  et  al.,  2014).  Cardiovascular  activity  was  monitored
throughout  tasks,  and  subjective  stress,  blood  and  saliva
samples  were  taken  immediately  after  tasks.  Monitoring  of
the  post-task  recovery  period  continued  for  75  min  and  addi-
tional  blood  samples  and  stress  ratings  at  45  and  75  min.
2.3.  Biological  measures
Blood  samples  were  collected  in  EDTA  tubes  and  centrifuged
immediately  at  2500  rpm  for  10  min  at  room  temperature.
Plasma  was  separated  and  stored  at  −80 ◦C  until  analysis.
Plasma  IL-6  was  assayed  using  a  high  sensitivity  Quantikine
two-site  enzyme-linked  immunosorbent  assay  (ELISA)  from
R&D  Systems  (Oxford,  UK).  The  sensitivity  of  the  assay
ranged  from  0.016  to  0.110  pg/ml  and  the  intra  and  inter
assay  coefﬁcient  of  variations  (CVs)  of  7.3%  and  7.7%  respec-
tively.  MCP-1  was  assayed  in  duplicate  using  the  ﬂuorokine
MAP  proﬁling  from  R&D  (Oxford,  UK),  and  concentrations
were  determined  with  Luminex  technology  from  Bio  Rad
(Bio-Plex,  Hercules,  CA,  US).  For  MCP-1  the  limit  of  detec-
tion  was  1.2  pg/ml  and  the  mean  intra  and  inter  assay  CVs
were  6.1%  and  12%  respectively.  Plasma  IL-6  and  MCP-1  were
assayed  from  all  four  blood  samples  i.e.  baseline,  task,  45
and  75  min  post-task,  whereas  HbA1c  was  analyzed  from  the
baseline  sample  alone.
2.4.  Glucocorticoid  function  assay  reagents
PBS  Gibco,  500  ml,  ref.  2012-019,  sterile  (Invitrogen);
RPMI  1640  medium  (Sigma),  500  ml,  sterile,  R8758;  DEX
(Sigma),  D4902;  PRED  (Sigma),  P-6004;  C7291;  peni-
cillin/streptomycin  (Sigma),  500  ml,  sterile,  P4458;  LPS
(Gibco,  catalog  20012-019,  Lot  L-2880);  Fetal  Calf  Serum
(Gibco  10270).
2.5.  Glucocorticoid  function  assay  protocol
The  protocol  was  based  on  a  published  method  (Carvalho
et  al.,  2008,  2010).  Glucocorticoid  function  was  measured
by  glucocorticoid  inhibition  of  LPS-stimulated  IL-6  levels.
Whole  blood  was  diluted  tenfold  with  RPMI  1640  medium,
supplemented  with  10%  foetal  calf  serum.  All  solutions
were  prepared  in  pyrogene-free  sterile  saline  (NaCl  0.9%)
to  achieve  ﬁnal  concentrations  in  the  cultures  of  0,  1,  10,
100,  1000  nM  for  DEX;  0,  1,  10,  100,  1000  nM  for  PRED.
A  total  of  540  ml  of  diluted  blood  (in  RPMI  1640  medium
with  L-glutamine  supplemented  with  100  IU/ml  penicillin
and  100  mg/ml  streptomycin)  was  added  onto  48-well  cell
culture  plates  (Falcon,  no.  3078).  LPS  and  glucocorticoids
were  subsequently  added  to  the  wells.  Samples  were  incu-
bated  for  24  h  in  a  humidiﬁed  atmosphere  containing  5%  CO2.
After  the  incubation,  plates  were  centrifuged  (1000  ×  g,
20  min)  and  supernatant  carefully  collected  and  kept  at
−70 ◦C  until  analysis.  Each  concentration  for  each  drug  was
performed  in  duplicates  and  always  by  the  same  researcher.
2.6.  Stimulated  IL-6  production  and  GC  sensitivity
All  analysis  for  IL-6  production  and  GC  sensitivity  was  carried
out  using  a  commercially  available  Luminex  technology  kit
for  IL-6  from  Bio-RAD®.  The  coefﬁcient  of  variation  (CV)  for
IL-6  analysis  was  4.7%  within  run  and  6.5%  in  between  runs,
and  the  detection  limit  was  2  pg/ml.
Glucocorticoid  (GC)  inhibition  was  calculated  by  con-
sidering  LPS-stimulated  IL-6  levels  in  the  absence  of
glucocorticoids  as  100%.  Speciﬁcally,  the  calculation  of  the
percentage  inhibition  in  glucocorticoids  condition  was  as
conducted  as  LPS-induced  IL-6  levels  in  the  presence  of
glucocorticoids,  divided  by  LPS-induced  IL-6  levels  in  the
absence  of  glucocorticoids  ×  100.
Percentage  inhibition  from  each  glucocorticoid  concen-
tration  were  inserted  in  GraphPad  Prism  (GraphPad  Software
Inc.,  San  Diego,  CA,  USA)  to  calculate  one  log  IC50 for  each
time-point.  We  estimated  log  IC50 (instead  of  raw  IC50)  due  to
superior  statistical  properties.  Log  IC50 values  are  inversely
proportional  to  glucocorticoid  sensitivity.  Higher  IC50 val-
ues  indicate  that  more  dexamethasone  or  prednisolone  is
needed  to  suppress  cytokine  production  by  50%,  and  thus
white  blood  cells  are  viewed  as  more  resistant  to  anti-
inﬂammatory  signals.
2.7.  Salivary  cortisol  over  the  day
Saliva  was  collected  over  the  course  of  a  single  day  within
the  seven  days  following  the  laboratory  testing.  Partici-
pants  were  asked  to  provide  ﬁve  samples  in  salivettes  over
the  course  of  a  normal  weekday  at  waking,  at  waking  plus
30  min,  10—10.30  am,  4—4.30  pm,  and  8—8.30  pm.  They
were  instructed  not  to  brush  their  teeth  or  eat  or  drink
anything  for  15  min  prior  to  sample  collection.  Information
on  the  day  of  sampling  was  recorded  in  a booklet,  which
included  information  on  time  of  waking,  and  the  time  each
sample  was  taken.  The  salivettes  and  booklet  were  posted
back  in  a  freepost  envelope.
2.8.  Statistical  analysis
We  computed  mean  systolic  BP,  diastolic  BP  and  heart  rate
for  ﬁve  5-min  periods  across  the  mental  stress  testing  ses-
sion:  baseline  (the  last  5  min  of  the  30  min  baseline  period),
the  two  task  periods,  and  post-stress  recovery  minutes
40—45  and  70—75.  The  two  task  trials  were  subsequently
averaged.  We  carried  out  generalized  linear  regression  to
assess  patterns  of  change  across  the  session,  with  group  and
time  of  session  (morning  or  afternoon)  as  between-person
factors  and  trial  as  the  within-person  factor.  Differences
between  groups  in  stress  reactivity  for  subjective  stress,
cardiovascular  variables,  cortisol  and  MCP-1  were  assessed
by  computing  difference  scores  between  task  and  baseline.
Stress  responses  in  IL-6,  and  glucocorticoid  sensitivity  are
delayed  in  comparison  with  other  measures,  so  we  assessed
reactivity  as  differences  between  values  recorded  at  45  min
and  75  min  compared  with  baseline.  Post-stress  recovery  in
cardiovascular  measures,  cortisol  and  MCP-1  was  measured
using  difference  scores  between  task  and  recovery  means.
Cortisol  was  analyzed  by  computing  cortisol  area  under  the
curve  (AUC)  using  procedures  described  by  (Pruessner  et  al.,
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2003)  to  investigate  total  cortisol  output  over  the  day.  Units
for  AUC:  (nmol/l)-h.
We  log  transformed  cortisol,  IL-6  and  MCP-1  to  normal-
ize  the  distribution.  All  analyses  of  physiological  data  were
adjusted  for  BMI  and  time  of  session.  There  were  no  associa-
tions  with  IC50 and  medication  types  and  thus,  as  covariates
in  GC  sensitivity  analysis  we  controlled  for  BMI  and  time  of
session.
Repeated  measures  analyses  were  conducted  using  all
measures  (baseline,  stress,  45  min  post-stress,  75  min  post-
stress).  Our  protocol  was  designed  to  assess  both  reactivity
and  recovery  processes.  To  capture  this  dynamics  the
contrasts  we  reported  quadratic  trends.  Finally,  for  each
outcome  we  report  a  within-subjects  contrast  for  the  effect
of  time,  which  reﬂects  the  extent  of  change  for  the  whole
sample  over  the  lab  session.  We  also  report  a  contrast  for
the  group  ×  time  interaction.
Because  of  occasional  technical  difﬁculties  with
venepuncture  and  laboratory  equipment,  reported  degrees
of  freedom  vary  slightly  from  analysis  to  analysis.  All  data
are  reported  as  mean  ±  SEM  unless  otherwise  noted.  Data
were  analysed  using  SPSS  statistical  software  package
version  22.0  (SPSS  Inc.,  Chicago,  IL,  USA).  All  testing  was
two-tailed  with  the  signiﬁcance  level  set  at  p  =  0.05.
3. Results
3.1.  Participant  characteristics
The  diabetes  group  consisted  of  23  men  and  14  women  with
an  average  age  of  64.8  ±  1.2  years.  The  diabetes  and  healthy
control  groups  did  not  differ  in  sex  distribution,  or  the  likeli-
hood  of  being  smokers,  marital  status,  or  paid  employment
(Table  1).  As  expected,  HbA1c,  BMI  and  waist  to  hip  ratio
were  greater  in  people  with  diabetes  than  controls.  The
majority  of  diabetic  participants  were  taking  oral  medica-
tions  (87%)  such  as  metformin,  hypertensive  medications
(75%)  and  statins  (80%).  None  of  the  participants  in  the  non-
diabetic  control  group  were  taking  any  medication.  Number
of  participants  seen  in  each  time  of  session  did  not  differ
between  groups  (morning:  HC  =  12,  DM  =  15,  and  afternoon:
HC  =  25,  DM  =  22,  2 =  0.315).
3.2.  Stress  changes
3.2.1.  Regulation  of  inﬂammatory  cytokines
There  was  no  difference  in  plasma  IL-6  levels  at  base-
line  between  diabetes  and  control  groups  (F(1,74) =  0.506,
p  =  0.48).  Analysis  revealed  that  there  was  an  effect  of  group
at  45  min  after  tasks  (F(1,74) =  9.005,  p  =  0.005)  demonstrat-
ing  an  increase  in  IL-6  levels  following  stress  only  in  healthy
controls,  but  no  change  in  diabetes  (Table  2).  There  was  no
main  effect  of  group  on  stress  responsivity  immediately  after
tasks  or  at  75  min.  However,  healthy  controls  had  higher  lev-
els  of  IL-6  at  45  min  (F  =  6.87,  p  =  0.011)  and  at  75  min  after
tasks  (F  =  5.56,  p  =  0.022)  than  at  baseline  (Fig.  1).
There  was  no  difference  in  plasma  MCP-1  at  base-
line  between  diabetes  and  control  groups  (F(1,74) =  0.737,
p  =  0.39).  There  was  a  signiﬁcant  effect  of  group  on  MCP-1
stress  recovery  at  75  min  (F  =  5.367,  p  =  0.024).  After  stress,
MCP-1  levels  decreased  in  diabetes  group,  but  increased
in  healthy  controls.  There  were  no  other  signiﬁcant  differ-
ences.
3.2.2.  IL-6  production  in  response  to  stress
Whole  blood  cells  from  diabetes  participants  were  less  capa-
ble  of  producing  IL-6  at  baseline  after  LPS  stimulation,  when
compared  with  healthy  controls  at  baseline  (F(1,49) =  5.755,
p  = 0.022).  There  was  no  effect  of  group  on  stress  respon-
sivity  or  recovery  of  IL-6  production,  when  controlled  for
BMI,  age,  baseline  values  and  time  of  session  (Fig.  1).  The
healthy  control  group  showed  a  decrease  in  IL-6  produc-
tion  (Mean  difference  −326  ±  151,  p  =  0.042)  in  the  45  min
recovery  compared  with  baseline,  which  returned  to  base-
line  levels  at  75  min  recovery  (Mean  difference  −9.2  ±  190,
p  = 0.96).  Exposure  to  stressor  did  not  change  IL-6  production
in  diabetes  participants  (Fig.  1).
3.2.3.  Glucocorticoid  sensitivity:  Dexamethasone-  and
prednisolone-  inhibition  of  LPS-induced  IL-6  production
The  diabetes  group  had  greater  dexamethasone
(F(1,39) =  9.586,  p  =  0.004),  but  similar  prednisolone  sen-
sitivity  (F(1,39) =  1.914,  p  =  0.175)  at  baseline  (Fig.  2).
Exposure  to  the  stress  tasks  inﬂuenced  the  sensitivity
of  white  blood  cells  to  the  anti-inﬂammatory  properties
of  glucocorticoids.  Following  exposure  to  the  stressor,
dexamethasone  and  prednisolone  sensitivity  did  not  change
among  the  diabetes  group,  whereas  it  decreased  among
controls  (Fig.  2).
Repeated  measures  ANOVA  revealed  the  contrasts  for
time  were  not  signiﬁcant  for  dexamethasone  (F  =  0.94,
p  = 0.338),  but  were  signiﬁcant  for  prednisolone  (F  =  4.214,
p  = 0.047).  There  was  a signiﬁcant  time  vs group  inter-
action  for  dexamethasone  (F  =  4.011,  p  =  0.050),  and  for
prednisolone  (F  =  4.998,  p  =  0.031),  supporting  a  signiﬁ-
cant  difference  in  stress  reactivity  of  prednisolone  and
dexamethasone  sensitivity  over  time  between  diabetes  par-
ticipants  and  healthy  controls.  In  healthy  controls,  there  was
a  progressive  desensitization  of  glucocorticoid  and  mineralo-
corticoid  sensitivity  after  stress  which  reached  signiﬁcance
during  45  min  of  the  recovery  period  compared  with  baseline
(dexamethasone  mean  difference  45  min,  −0.18,  p  =  0.012;
prednisolone  mean  difference  45  min,  −0.39,  p  =  0.034);  at
75  min  glucocorticoid  and  mineralocorticoid  sensitivity  had
returned  to  baseline  values  (dexamethasone,  mean  differ-
ence  -0.07,  p  =  0.35;  prednisolone  mean  difference  −0.16,
p  = 0.39)  in  healthy  controls.  There  was  no  change  in  gluco-
corticoid  or  mineralocorticoid  sensitivity  after  stress  in  the
diabetes  group.
3.2.4.  Physiological  responses  to  mental  stress
The  mental  stress  tasks  elicited  substantial  subjective
stress  responses  with  increases  from  1.68  ±  (SEM)  0.19
to  4.86  ±  0.19  in  the  diabetes  and  1.38  ±  (SEM)  0.10  to
4.89  ±  0.18  in  controls.  There  were  no  differences  in  sub-
jective  stress  at  baseline  between  diabetes  and  healthy
controls  (F  =  0.018,  p  =  0.892).  The  increase  in  subjective
stress  ratings  did  not  differ  between  groups.  In  sum,
there  was  no  difference  in  task  engagement  between
groups.
Systolic  diastolic  BP  and  heart  rate  rose  during  stress
tasks,  returning  towards  baseline  over  the  post-stress
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Table  1  Clinical  and  demographics  characteristics  of  healthy  controls  and  diabetes.
Demographic  characteristics  Diabetes  (N  =  37)  Control  (N  =  37)  P  value/2
Age  (years)  64.8  ±  1.23  67.53  ±  0.77  0.063
Sex (male,  N  (%))  23  (64%)  20  (54%)  0.638
Paid employment  N  (%)  12  (32%)  9  (25%)  0.607
Marital status  (single/divorced)  16(43%)  8(22%)  0.041
Income (<40k)  28(76%)  12(32%)  <0.001
Current smokers  3  (8%)  0  (0%)  0.120
HbA1c (%)  7.13  ±  0.18  5.68  ±  0.048  <0.001
Body mass  index  (kg/m2) 26.7  ±  0.7  31.6  ±  1.9  <0.001
WHR 1.01  ±  0.01 0.88  ±  0.01 <0.001
Medication—–N (%)
Statins  31  (84%) —
Oral diabetic  medication  31  (84%)  —
Insulin, other  diabetic  medication  2  (0.05%)  —
Aspirin 15  (40%)  —
Beta-blockers  3  (0.08%)  —
Other anti-hypertensive  medication  28  (76%)  —
Values are mean ± SEM or number of participants (% of sample). CES-D—–centre for epidemiologic studies depression (Scale); WHR:
waist-to-hip ratio; HbA1c—–glycated haemoglobin.
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Fig.  1  Mean  IL-6,  MCP-1  and  IL-6  production  in  the  diabetes  (circles)  and  no  diabetes  (square)  groups  sampled  at  baseline,
immediately  after  tasks,  and  45  and  75  min  later.  Values  are  adjusted  for  sex,  BMI,  and  time  of  testing.  Error  bars  are  S.E.M.  pl—
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A)
B)
Fig.  2  Mean  IC50 values  for  dexamethasone  (A)  and  pred-
nisolone  (B)  in  diabetes  (circles)  and  healthy  controls  (square).
This ﬁgure  shows  that  diabetes  moderates  the  impact  of
acute stress  on  the  immune  system’s  sensitivity  to  the  anti-
inﬂammatory  properties  of  glucocorticoids  via  GR  and  MR.  IC50
was  calculated  by  dexamethasone  and  prednisolone  inhibition
of LPS-induced  IL-6  levels.  HC—–healthy  controls;  DM—–diabetes
mellitus.
recovery  period  in  both  groups  (Fig.  3).  The  diabetes
group  showed  a  reduced  pattern  of  cardiovascular  response
to  stress.  Notably,  systolic  BP  stress  reactivity  (F  = 5.007,
p  =  0.029),  and  heart  rate  stress  reactivity  (F  =  3.327,
p  =  0.039)  were  blunted  in  the  diabetes  compared  with
healthy  controls  group.  Heart  rate  post-stress  recovery  at
45  min  (F  =  13.624,  p  <  0.001)  and  at  75  min  (F  =  8.116,  0.006)
were  blunted  in  the  diabetes  compared  with  the  control
(Fig.  3).
3.2.5.  Cortisol  stress  reactivity
There  was  no  difference  in  baseline  cortisol  levels  in
diabetes  compared  with  healthy  controls  (F(1,70) =  1.174,
p  =  0.283)  when  controlled  for  age,  gender,  BMI  and  time
of  session.  There  was  a  main  effect  of  group  on  corti-
sol  stress  response  immediately  following  tasks  (F  =  4.214,
p  =  0.044),  since  only  in  the  diabetes  group  cortisol  lev-
els  fell.  Cortisol  levels  went  back  to  baseline  levels  during
the  recovery  period  (Fig.  4).  There  were  no  main  effect
of  group  on  cortisol  levels  measured  repeatedly  over  the
session  (F(1,66) =  0.465,  p  =  0.49).
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Fig.  3  Mean  systolic  BP  (upper  panel),  diastolic  BP  (cen-
ter panel)  and  heart  rate  (lower  panel)  during  baseline,  task
trials,  and  40—45  min  and  70—75  min  post-tasks  in  the  dia-
betes  (circles)  and  no  diabetes  (square)  groups.  BP  data  are
adjusted  for  sex,  BMI,  smoking  status  and  beta-blocker  use,
and heart  rate  for  sex,  BMI,  smoking  status,  oral  diabetic
medication  and  beta-blocker  use.  P  values  indicate  group  dif-
ferences  in  stress  reactivity  (baseline—–task  difference)  and
post-stress  recovery  (task—–post-task  differences.  Error  bars  are
standard  errors  of  the  mean  (s.e.m.).  HC—–healthy  controls;
DM—–diabetes  mellitus.
3.3.  Cortisol  samples  over  the  day
Diabetes  participants  had  increased  cortisol  levels  when
compared  to  healthy  controls  as  shown  by  higher  AUC  over
the  day  (DM  99.19  ±  12.62,  HC  75.47  ±  6.04,  F(1,62) =  35.392,
p  < 0.001).  Diabetes  participants  had  blunted  levels  of
cortisol  at  awakening  (DM  16.69  ±  1.72,  HC  19.82  ±  1.53,
F(1,66) =  3.812,  p  =  0.05),  when  controlled  for  age,  gender  and
BMI.  There  was  no  group  difference  in  the  cortisol  awakening
response.
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Fig.  4  Mean  salivary  cortisol  in  the  diabetes  (circles)  and  no
diabetes  (square)  groups.  Cortisol  sampled  at  baseline,  imme-
diately  after  tasks,  and  20,  45  and  75  min  later.  Values  are
adjusted  for  sex,  BMI,  and  time  of  testing.  Error  bars  are  s.e.m.
HC—–healthy  controls;  DM—–diabetes  mellitus;  post-str1—–20  min
after task;  post-str2—–40—45  min  after  task  and  post-str3—–
70—75 min  after  task.
3.4.  Correlations
Baseline  LogIC50 was  negatively  associated  with  HbA1c  levels
in  the  diabetes  group  (DEX,  ˇ  =  −0.847,  t =  −6.79,  p  <  0.001;
PRED,  ˇ  =  −0.724,  t =  −5.85,  p  <  0.001)  and  healthy  con-
trols  (DEX  ˇ  =  −0.942,  t =  −8.58,  p  <  0.001;  PRED  ˇ  =  −0.577,
t  =  −5.27,  p  <  0.001).  Therefore,  at  baseline  resistance  to
anti-inﬂammatory  signals  is  negatively  associated  to  poor
glycaemic  control  in  both  groups.  HbA1c  inversely  associated
to  MCP-1  stress  response  at  75  min  in  diabetic  participants
(ˇ  =  −0.081,  t  =  −0.39,  p  =  0.026),  but  not  in  healthy  controls
(ˇ  =  −0.054,  t  =  −0.24,  p  =  0.142).  Thus,  the  lower  MCP-1
stress  response  in  diabetes  the  worse  the  glucose  regula-
tion.  The  dexamethasone  IC50 stress  response  was  positively
associated  to  MCP-1  stress  response  at  45  min  in  healthy
controls  (ˇ  =  0.492,  t  =  2.28,  p  =  0.034),  but  not  in  diabetes
(ˇ  =  −0.043,  t  =  −0.17,  p  =  0.865).  Thus,  the  higher  MCP-1
after  stress  the  higher  the  resistance  to  anti-inﬂammatory
signals  in  healthy  controls.  The  prednisolone  IC50 stress
response  was  positively  associated  with  the  IL-6  stress
response  at  45  min  in  the  diabetes  group  (ˇ  = 0.518,  t  =  2.37,
p  =  0.032),  but  the  association  in  controls  did  not  reach  sig-
niﬁcance  (ˇ  =  0.527,  t =  0.186,  p  =  0.081).
4. Discussion
This  study  investigated  whether  psychological  stress,  man-
ifested  in  alterations  in  dynamic  physiological  responses
to  standardized  mental  stress  is  associated  with  impair-
ment  of  glucocorticoid  and  mineralocorticoid  sensitivity  in
type  2  diabetes.  The  diabetes  group  were  more  sensitive
to  the  immunosuppressive  actions  of  glucocorticoids  in  the
beginning  of  the  session.  Following  exposure  to  stress,  both
glucocorticoid  and  mineralocorticoid  sensitivity  decreased
among  controls  whilst  no  change  was  observed  in  dia-
betes  participants.  Glucocorticoid  sensitivity  was  inversely
associated  with  HbA1c  indicating  that  people  with  higher
glucocorticoid  sensitivity  had  poorer  control  of  blood  glu-
cose  levels.  We  also  found  that  the  diabetes  group  showed
blunted  stress  reactivity  in  systolic  BP,  heart  rate,  IL-6,
and  impaired  post-stress  recovery  in  MCP-1  and  heart  rate.
Taking  together,  diabetes  is  associated  with  attenuated
responsiveness  to  psychological  stress,  and  a  lack  of  stress-
induced  modulation  of  glucocorticoid  and  mineralocorticoid
sensitivity.
At  baseline,  diabetes  patients  had  increased  glu-
cocorticoid,  but  normal  mineralocorticoid  sensitivity  in
the  presence  of  hypercortisolemia.  The  action  of  dex-
amethasone—–which  exclusively  binds  to  GR  —  and  of
prednisolone—–which  binds  to  both  GR  and  MR  —  is  respec-
tively  a  proxy  for  glucocorticoid  and  mineralocorticoid
sensitivity  (Juruena  et  al.,  2009).  Upon  ligand  binding,
corticosteroid  receptors  are  activated  and  translocate  to
the  nucleus  where  it  transmits  the  anti-inﬂammatory  prop-
erty  of  corticosteroids.  In  healthy  participants,  subsequent
GR  and  MR  down-regulation  occurs.  In  the  presence  of
chronic  hormone  exposure  decreased  glucocorticoid  sensi-
tivity  is  expected  in  order  to  maintain  overall  effect  of
cortisol  in  peripheral  tissue.  This  was  not  the  case  in  dia-
betes  participants.  Contrary  to  our  study,  Hudson  et  al.
(1984)  showed  decreased  response  in  the  dexamethasone
suppression  test  in  type  1  and  type  2  diabetes  partici-
pants  (Hudson  et  al.,  1984).  Dexamethasone  suppression
was  also  analysed  in  another  large  group  of  diabetes,  but
without  a  group  of  healthy  controls  direct  comparison  can-
not  be  made  (Kaye  et  al.,  1992).  Despite  the  well-known
relationship  between  circulating  aldosterone  with  insulin
resistance  (Lastra-Gonzalez  et  al.,  2008;  Briet  and  Schiffrin,
2011),  diabetes  participants  showed  normal  mineralocor-
ticoid  sensitivity  at  baseline  when  compared  to  healthy
controls.  Similar  pattern  have  been  observed  in  people  with
post-traumatic  stress  disorder  (Yehuda  et  al.,  2006),  and  in
people  with  mild  depression  (Miller  et  al.,  2005),  but  are
in  contrast  to  people  with  severe  major  depression  (Bauer
et  al.,  2003).  Such  disturbance  in  the  regulation  of  the
HPA  axis  may  contribute  to  deterioration  in  diabetes  by
enhancing  the  effect  of  cortisol  and  its  anti-insulin  actions,
including  the  inhibition  of  glucose  uptake  in  adipocytes  and
ﬁbroblasts,  increasing  hepatic  gluconeogenesis,  sensitizing
the  liver  to  catecholamines  and  glucagon,  and  elevating
blood  glucose  (Chan  et  al.,  2003).  In  accordance,  we  found
increased  baseline  corticosteroid  sensitivity  associated  with
poorer  glucose  control.
Our  study  suggests  that  in  diabetes  the  ability  to  match
the  body’s  response  to  a  stressor  involves  modulation  of  cor-
ticosteroid  receptor  sensitivity,  an  evidence  of  insufﬁcient
corticosteroid  signalling.  Reduced  corticosteroid  receptor
stress  responsivity  has  been  previously  shown  in  the  hip-
pocampus  of  diabetic  mice  (Chan  et  al.,  2002,  2003,  2005).
Reduced  glucocorticoid  responses  to  a  laboratory  stressor
have  been  shown  previously  in  middle-aged  men  with  a  high
body  mass  index  (Ljung  et  al.,  2000).  Insufﬁcient  corticoste-
roid  signalling  may  release  inﬂammatory  markers  previously
under  inhibitory  glucocorticoid-mediated  control  and  con-
tribute  to  altered  glucose  metabolism  (Raison  and  Miller,
2003).  In  accordance,  it  was  observed  by  this  study  and
by  others  that  pro-inﬂammatory  cytokines  are  increased
in  patients  with  diabetes,  obesity  and  insulin  resistance
(Fernandez-Real  and  Ricart,  1999;  Fernandez-Real  et  al.,
2001;  Kern  et  al.,  2001).  Moreover,  insufﬁcient  corticoste-
roid  signalling  may  also  increase  arousal  and  thus  play  a
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role  in  stress-related  pathology.  Glucocorticoid  sensitivity
can  be  activated  by  -adrenergic  agonists  via  a  cortisol-
independent  mechanism  (Eickelberg  et  al.,  1999).  In  our
study,  there  was  a  limited  cortisol  response  to  psychological
stress  even  in  healthy  controls.  Nevertheless,  corticosteroid
sensitivity  decreased  after  stress  in  healthy  controls,  but  not
in  diabetes  participants.  It  is  thus  possible  that  the  reduced
corticosteroid  stress  responsivity  in  diabetes  participants
involves  impairment  of  the  -adrenergic  pathways.
In  accordance  to  an  impairment  of  -adrenergic  path-
ways,  diabetes  participants  showed  blunted  stress  reactivity
in  systolic  BP,  IL-6  and  impaired  post-stress  recovery  in  MCP-
1  and  heart  rate.  Blunted  stress  reactivity  in  diabetes  was
conﬁrmed  by  us  in  a  recent  larger  study  (Steptoe  et  al.,
2014)  where  this  sub-group  came  from.  Other  types  of
stressor  then  the  one  used  in  this  study  —  such  as  socially-
evaluative  threat  —  are  associated  with  bigger  activation
of  the  HPA  axis  (Dickerson  and  Kemeny,  2004;  Gruenewald
et  al.,  2004).  Biological  responses  to  stress  in  healthy
controls  were  of  similar  magnitude  then  what  has  been  pre-
viously  described  (Steptoe  and  Cropley,  2000;  Steptoe  et  al.,
2002b,  2007;  Hamer  et  al.,  2010;  Hackett  et  al.,  2012).
This  study  has  several  limitations.  It  was  cross  sectional
in  nature  and  no  causal  conclusions  can  be  drawn.  Our  study
did  not  greatly  alter  salivary  cortisol  levels  possibly  due
to  the  small  sample  size,  and  results  may  differ  if  other
types  of  stressors  were  used.  Our  interpretation  must  take
into  account  that  cortisol  plasma  levels  responses  were  not
reﬂected  in  absolute  increases  in  levels,  but  in  differences
in  rates  of  decline.  This  is  likely  due  to  the  overlay  of  diurnal
cortisol  rhythms.  Cortisol  stress  reactivity  might  have  been
different  if  all  experiments  were  conducted  in  the  after-
noon,  when  cortisol  diurnal  rhythm  is  not  so  obvious,  though
this  factor  is  unlikely  to  have  inﬂuenced  our  results  since  all
analysis  were  corrected  for  time  of  session.  In  any  case,  cor-
ticosteroid  sensitivity  function  seems  to  be  more  sensitive  to
stress-related  changes  than  actual  cortisol  levels.  Although
studies  have  shown  that  measuring  cortisol  proﬁle  over  one
day  only  is  reliable  (Kraemer  et  al.,  2006),  measuring  corti-
sol  proﬁle  over  two  days  might  better  reﬂect  actual  HPA  axis
disturbances.  Nevertheless,  these  ﬁndings  shed  additional
light  on  stress-related  mechanisms  in  diabetes  participants.
5. Conclusion
We  have  shown  that  diabetes  is  associated  with  a  lack  of
stress-induced  modulation  of  glucocorticoid  and  mineralo-
corticoid  sensitivity.  Emphasis  on  modulating  glucocorticoids
in  stress-related  pathology  encourages  development  of
therapeutic  strategies  to  modulate  glucocorticoid-signalling
pathways.
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